{"title": "Bayer's Kerendia/SGLT2 combo exceeds expectations, with more expansion ahead: pharma chief", "author": "Angus Liu", "url": "https://www.fiercepharma.com/pharma/bayer-s-kerendia-sglt2-combo-showing-exceeds-expectation-heart-disease-diabetes-pharma-chief", "hostname": "fiercepharma.com", "description": "Bayer's heart and kidney disease drug Kerendia is considered a rival to well-established SGLT2 diabetes meds. | Bayer's heart and kidney disease drug Kerendia is considered a rival to well-established SGLT2 diabetes meds. But after new data showed the two types of medicines can work together, the German company is getting even more bullish about Kerendia's potential.", "sitename": "FiercePharma", "date": "2021-11-09", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}